CereGate GmbH

CereGate GmbH focuses on developing innovative computer-brain interface solutions aimed at restoring sensory functions and addressing neurological disorders through advanced neural communication technologies. CereGate GmbH, founded in 2019, is headquartered in Hamburg, Germany. The company specializes in computer-brain interface technology and has completed a total of three deals as of September 2020. Bálint Várkuti serves as both the CEO and founder, leading the firm through its initial development phase.

CereGate specializes in a computer-brain interface platform designed to enhance human sensory capabilities. This hardware-agnostic platform offers various therapeutic solutions for neurological disorders and sensory impairments, including advanced neural communication technologies that facilitate direct brain-device interaction. Its products are utilized in clinical settings for rehabilitation and cater to research institutions within North America and Europe, serving clients such as hospitals and academic research facilities. CereGate generates revenue through direct sales to healthcare providers and partnerships with research institutions.

Their transactions typically involve licensing technology and selling therapeutic devices, which may be structured as subscriptions or one-time hardware purchases. Their revenue model is designed to foster close relationships with clients in the healthcare sector, ensuring tailored solutions for various applications. CereGate plans to leverage the recent Series A funding raised in September 2020 to expand its product offerings and market reach. This funding will support the development of new products aimed at enhancing their therapeutic capabilities.

The company is also targeting expansion into additional markets in Europe and North America by 2022, focusing on increasing accessibility to their solutions for healthcare providers and research institutions.